Advertisement

Coronary Intervention and Ischemic Cardioprotection in Diabetic Patients

  • Torsten Toftegaard Nielsen

Keywords: Coronary angiography, percutaneous intervention (PCI), coronary bypass surgery (CABG), Testenosis, acute myocardial infarction, insulinglucose infusion.

Keywords

Diabetic Patient Percutaneous Coronary Intervention Acute Myocardial Infarction Primary Percutaneous Coronary Intervention Coronary Heart Disease Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463–524.CrossRefPubMedGoogle Scholar
  2. 2.
    Laskey WK, Selzer F, Vlacvhos HA, Johnston J, Jacobs A, King SB III, Holmes DR, Douglas J, Block P, Wilensky R, Williams DO, Detre K. Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (form the National Heart, Lung and Blood Institute Dynamic Registry). Am J Cardiol 2002;90:1062–1067.CrossRefPubMedGoogle Scholar
  3. 3.
    Sobel BE, Frye R, Detre KM. Burgeoning dilemmas in the management of diabetes and cardiovascular disease. Rationale for the Bypass Angioplasty Revascularization Investigation 2 D (BARI 2D) trial. Circulation 2003;107:636–642.CrossRefPubMedGoogle Scholar
  4. 4.
    Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997;349:1498–1504.CrossRefPubMedGoogle Scholar
  5. 5.
    Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Eng J Med 1998;339:229–234.CrossRefGoogle Scholar
  6. 6.
    Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, Fayad Z, Budoff MJ, Rumberger J, Naqvi TZ, Shaw LJ, Faergeman O, Cohn J, Bahr R, Koenig W, Demirovic J, Arking D, Herrera VL, Badimon J, Goldstein JA, Rudy Y, Airaksinen J, Schwartz RS, Riley WA, Mendes RA, Douglas P, Shah PK. From vulnerable plaque to vulnerable patient – part III: Executive summary of screening for heart attack prevention and education (SHAPE) task force report. Am J Cardiol 2006;98:2H–15H.CrossRefPubMedGoogle Scholar
  7. 7.
    Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol 2006:47:C7–C12.CrossRefPubMedGoogle Scholar
  8. 8.
    Saely CH, Aczel S, Marte T, Langer P, Drexel H. Cardiovascular complications in type 2 diabetes mellitus depend on the coronary angiographic state rather than on the diabetic state. Diabetologia 2004;47:145–146.CrossRefPubMedGoogle Scholar
  9. 9.
    Eberly LE, Cohen JD, Prineas R, Yang L. Multiple Risk Factor Intervention Trial Research Group. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality. Diabetes Care 2003;26:848–854.CrossRefPubMedGoogle Scholar
  10. 10.
    Clouse ME, Chen J, Krumholz HM. Noninvasive screening for coronary artery disease with computed tomography is useful. Circulation 2006;113:125–146.CrossRefPubMedGoogle Scholar
  11. 11.
    Kim WY, Danias PG, Stuber M, Flamm SD, Plein S, Nagel E, Langerak SE, Weber OM, Pedersen EM, Schmidt M, Botnar RM, Manning WJ. Coronary magnetic resonance angiography for detection of coronary stenosis. N Engl J Med 2001;345:1863–1869.CrossRefPubMedGoogle Scholar
  12. 12.
    Purushothaman KR, Sanz J, Zias E, Fuster V, Moreno PR. Atherosclerosis neovascularisation and imaging. Curr Mol Med 2006;6:549–556.CrossRefPubMedGoogle Scholar
  13. 13.
    Kim WY, Astrup AS, Stuber M, Tarnow L, Falk E, Botnar RM, Simonson C, Pietraszek L, Hansen PR, Manning WJ, Andersen NT, Parving HH. Subclinical coronary and aortic atherosclerosis detected by magnetic resonance imaging in type 1 diabetes with and without diabetic nephropathy. Circulation 2007;115:180–187.CrossRefGoogle Scholar
  14. 14.
    Johnsen SP, Videbaek J, Pedersen L, Steffensen R, Videbaek R, Niemann T, Nielsen TT, Sørensen HT. Survival trends among Danish patients undergoing coronary angiography for known or suspected ischemic heart disease: a population based follow up study, 1992–2000. Heart 2006;92:27–31.CrossRefPubMedGoogle Scholar
  15. 15.
    Rodriguez A, Boullon F, Perez-Balino N, Paviotti C, Liprandi MI, Palacios IF. Argentina randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI); in-hospital results and 1-year follow-up. J Am Coll Cardiol 1993;22:1060–1067.PubMedCrossRefGoogle Scholar
  16. 16.
    King SB III, Lembo NJ, Weintraub WS, Kosonski AS, Barnhart HX, Kutner MH, Alazraki NP, Guyton RA, Zhao XQ. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med 1994;331:1044–1050.CrossRefPubMedGoogle Scholar
  17. 17.
    First-year results of CABRI (Coronary Angioplasty versus Revascularization Investigation). CABRI Trial Participants. Lancet 1995;346:1179–1184.Google Scholar
  18. 18.
    The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217–225.CrossRefGoogle Scholar
  19. 19.
    Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ. Schonberger JP, Buller N, Bonser R, van den Brand MJB, van Herwerden LA, Morel MA, van Hout BA,–The Arterial Revascularization Therapies Study Group. Comparison of coronary bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117–1124.CrossRefPubMedGoogle Scholar
  20. 20.
    Detre KM, Guo P, Holubkov R, Califf RM, Sopko G, Bach R, Brooks MM, Bourassa MG, Shemin RJ, Rosen AD, Krone RJ, Frye RL, Feit F. Coronary revascularization in diabetic patients: A comparison of the randomized and observational components of the bypass angioplasty revascularization investigation (BARI). Circulation 1999;99:633–640.PubMedGoogle Scholar
  21. 21.
    Holmes DR Jr, Vlietstra RE, Smith HC, Vetrovec, GW, Kent KM, Cowley HJ, Faxon DP, Gruentzig AR, Kelsey SF, Detre KM. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung and Blood Institute. Am J Cardiol 1984;53:77C–81C.CrossRefPubMedGoogle Scholar
  22. 22.
    Mak KH, Faxon DP. Clinical studies on coronary revascularization in patients with type 2 diabetes. Eur Heart J 2003;24:1087–1103.CrossRefPubMedGoogle Scholar
  23. 23.
    Meheran R, Dangas GD, Kobayashi Y, Lansky AJ, Mintz GS, Aymong ED, Fahy M, Moses JW, Stone GW, Leon MB. Short- and long-term results after multivessel stenting in diabetic patients. Am J. Coll Cardiol 2004;43:1348–1154.CrossRefGoogle Scholar
  24. 24.
    Scheen AJ, Warzée F, Legard VMG. Drug-eluting stents: meta-analysis in diabetic patients. Eur Heart J 2004;25:2167–2176.CrossRefPubMedGoogle Scholar
  25. 25.
    Sabaté M, Jiménez-Quevedo PJ, Angioolillo DJ, Gómez-Hospital JA, Alfonso F, Hernández-Antolin R, Goicolea J, Bañuelos C, Escaned J, Moreno R, Fernández C, Fernández-Abilés F, Macaya C. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients (Diabetes Trial). Circulation 2005;112:2175–2183.CrossRefPubMedGoogle Scholar
  26. 26.
    Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russel ME. One-year clinical results with the slow-release, polymer based, paclitaxel-eluting taxus stent. The taxus-IV trial. Circulation 2004;109:1942–1947.CrossRefPubMedGoogle Scholar
  27. 27.
    Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006:27:2784–2814.CrossRefPubMedGoogle Scholar
  28. 28.
    Kastrai A, Mehelli J, Pache J, Kaiser C, Valgimigli M, Kelbæk H, Menichelli M, Sabaté M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schörnig A. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356;1030–1039.CrossRefGoogle Scholar
  29. 29.
    Maisel WH. Unanswered questions – Drug-eluting stents and the risk of late thrombosis. N Engl J Med 2007;356:981–984.CrossRefPubMedGoogle Scholar
  30. 30.
    Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S, Yoshida K. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus. J Am Coll Cardiol 2000;36:1529–1535.CrossRefPubMedGoogle Scholar
  31. 31.
    Fragmin and Fast Revascularisation during instability in Coronary artery disease (FRISCII) investigators. Invasive compared with non-invasive treatment, in unstable coronary-artery disease:FRISCII prospective randomised multicenter study. Lancet 1999; 354:708–715.Google Scholar
  32. 32.
    Fox KA, Pool-Wilson PA, Henderson RA, Clayton TC, Chamberlain Da, Show TR, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction; the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 2002;360:743–751.CrossRefPubMedGoogle Scholar
  33. 33.
    Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, Abildgaard U, Pedersen F, Madsen JK, Grande P, Villadsen AB, Krusell LR, Haghfelt T, Lomholt P, Husted SE, Vigholt E, Kjaergaard HK, Mortensen LS. DANAMI-2 investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349:733–742.CrossRefPubMedGoogle Scholar
  34. 34.
    Boersma E, and the (PCAT)-2 trialists collaborative group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006;27:779–788.CrossRefPubMedGoogle Scholar
  35. 35.
    Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D, Marre M, Steg PG, Gowda N, Gore JM. GRACE investigators. Implications of diabetes in patients with acute coronary syndromes. The global Registry of Acute Coronary Events. Arch Intern Med 2004;164:1457–1463.CrossRefPubMedGoogle Scholar
  36. 36.
    Norhammer A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Rydén L, Wallentin L. Diabetes mellitus: The major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol 2004;43:585–591.CrossRefGoogle Scholar
  37. 37.
    Henriques JPS, Zijlstra F, van't Hof AWJ, de Boer MJ, Dambrink JHE, Gosselink ATM, Hoorntje JCA, Ottervang JP, Suryapranata H. Primary percutaneous coronary intervention versus thrombolytic treatment: long term follow up according to infarct location. Heart 2006;92:75–79.CrossRefPubMedGoogle Scholar
  38. 38.
    Hsu LF, Mak KH, Lau KW, Sim LL, Chan C, Koh TH, Chiah SC, Kam R, Ding ZP, Teo WS, Lim YL. Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis. Heart 200;88:260–265.Google Scholar
  39. 39.
    Madsen MM, Busk M, Søndergaard HM, Bottcher M, Mortensen LS, Andersen HR, Nielsen TT. DANAMI-2 investigators. Does diabetes mellitus abolish the beneficial effect of primary coronary angioplasty on long-term risk of reinfarction after acute ST-segment elevation myocardial infarction compared with fibrinolysis? Am J Cardiol 2005;96:1469–1475.CrossRefPubMedGoogle Scholar
  40. 40.
    Busk M, Mortensen LS, Thuesen L, Andersen HR, Rasmussen K, Madsen JK, Nielsen TT. Reinfarction after anterior ST-elevation myocardial infarction: initial benefit of primary angioplasty compared to fibrinolysis is lost during long-term follow up. Circulation 2005;112(Suppl. II):569.Google Scholar
  41. 41.
    Cutlip DE, Chhabra AG, Baim DS, Chauhan MS, Marulkar S, Massaro J, Bakhai A, Cohen DJ, Kuntz RE, Ho KK. Beyond restenosis. Five-year clinical outcome from second-generation coronary stent trials. Circulation 2004;110:1226–230.CrossRefPubMedGoogle Scholar
  42. 42.
    Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic event. Diabetes care 2003;26:2181–2188.CrossRefPubMedGoogle Scholar
  43. 43.
    Marso SP, Lincoff M, Elklis SG, Bhatt DL, Tanguay JF, Kleiman NS, Hammoud T, Booth JE, Sapp SK, Topol EJ. Optimizing the percutaneous interventional outcomes for patients with diabetes. Results from the Epistent Diabetic Substudy. Circulation 1999;100:2477–2484.PubMedGoogle Scholar
  44. 44.
    Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS, Theroux P, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001;104:2767–2771.CrossRefPubMedGoogle Scholar
  45. 45.
    Mehilli J, Kastrati A, Schuhlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A. ISAR-SWEET Study Investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary intervention after treatment with a high loading dose of clopidogrel. Circulation 2004;110:3627–3635.CrossRefPubMedGoogle Scholar
  46. 46.
    Biondi-Zoccai GG, Abbate A, Liuzzo G, Biasucci LN. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 2003;41:1071–1077.CrossRefPubMedGoogle Scholar
  47. 47.
    The APEX AMI investigators. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention. A randomized controlled trial. JAMA 2007;297:43–51.CrossRefGoogle Scholar
  48. 48.
    UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.CrossRefGoogle Scholar
  49. 49.
    Stratton IM, Adler AI, Neil AW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR, UKPDS Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):prospective observational study. BMJ 2000;321:405–412.CrossRefPubMedGoogle Scholar
  50. 50.
    DDCT/EDIC Study Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003;348:2294–2303.CrossRefGoogle Scholar
  51. 51.
    DDCT/EDIC Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653.CrossRefGoogle Scholar
  52. 52.
    Proactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomized controlled trial. Lancet 2005;366:1279–1289.CrossRefGoogle Scholar
  53. 53.
    Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, Timmis GC, Balasubramaniam M, O'Neill WW. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004;43:8–14.CrossRefPubMedGoogle Scholar
  54. 54.
    Mazeika P, Prasad N, Bui S, Seidelin PH. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J 2003;145:1013–1021.CrossRefPubMedGoogle Scholar
  55. 55.
    Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K, Kuroda T, Tanaka K, Masuyama T, Hori M, Fujii K. Association between hyperglycemia and the no-flow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003;41:1–7.CrossRefPubMedGoogle Scholar
  56. 56.
    Timmer JR, van der Horst ICC, de Luca G, Ottervanger JP, Hoorntje JCA, de Boer MJ, Suryapranata H, Dambrink JHE, Gosselink M, Zijlstra F, van't Hof AWJ. Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with and without diabetes mellitus. Am J Cardiol 2005;95:1375–1377.CrossRefPubMedGoogle Scholar
  57. 57.
    van der Horst ICC, Zijlstra F, van't Hof AWJ, Doggen CJM, de Boer MJ, Suryapranata H, Hoorntje JCA, Dambrink JHE, Gans ROB, Bilo HJG. Glucose-insulin potassium infusion in patients treated with primary angioplasty for acute myocardial infarction. The glucose-insulin-potassium study: a randomized study. J Am Coll Cardiol 2003;42:784–791.CrossRefPubMedGoogle Scholar
  58. 58.
    Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendric S, Fisher M, Hamsten A, Herlitz J, Hildebrandt P, Macleod K, Laakso M, Torp-Pedersen C, Waldenström A. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26:650–661.CrossRefPubMedGoogle Scholar
  59. 59.
    The CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction. The Create-Ecla randomized controlled trial. JAMA 2005;293:437–446.Google Scholar
  60. 60.
    The task force on diabetes and cardiovascular diseases of the European Society of cardiologi (ESC) and of the European Association for the Study of Diabetes (EASD).Guidelines on diabetes, pre-diabetes, and cardiovascular Diseases: executive summary. Eur Heart J 2007;28:88–136.Google Scholar
  61. 61.
    van den Bergie G, Wouters P, Weekes F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin treatment in critically ill patients. N Engl J Med 2001;345:1359–1367.CrossRefGoogle Scholar
  62. 62.
    van der Voort PHJ, Feenstra RA, Bakkert AJ, de Heide L, Boerma C, van der Horst ICC. Intravenous glucose intake independently related to intensive care unit and hospital mortality: an argument for glucose toxicity in critically ill patients. Clinical Endocrinol 2006;64:141–145.CrossRefGoogle Scholar
  63. 63.
    Malmberg K, Norhammer A, Wedel H, Rydén L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose infusion in Acute Myocardial Infarction (DIGAMI) Study. Circulation 1999;99:2626–2632.PubMedGoogle Scholar
  64. 64.
    Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, Cannon CP, Braunwald E, Gibson CM (TIMI study group). U-shaped relationship of blood glucose with adverse outcomes among patients with ST- segment elevation myocardial infarction. J Am Coll Cardiol 2005;46:178–180.CrossRefPubMedGoogle Scholar
  65. 65.
    Goyal A, Mahaffey KW, Garg J, Nicolau JC, Hochman JS, Weaver WD, Therous P, Oliveira GBF, Todaro TG, Mojcik CF, Armstrong PW, Ganger CB. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J 2006;27:1289–1297.CrossRefPubMedGoogle Scholar
  66. 66.
    Norhammer A, Tenerz Aa, Nilsson G, Hamsten A, Efrendíc S, Rydén L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140–2144.CrossRefGoogle Scholar
  67. 67.
    The DECODE Study Group Consequences of the new diagnostic criteria for Diabetes in older men and women. DECODE Study (Diabetes epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). Diabetes Care 1999;22:1667–671.Google Scholar
  68. 68.
    Anselimo M, Bartnik M, Malmberg K, Rydén L. Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptable poor: a report from the Euro Heart Survey on Diabetes and the heart. Eur J Cardiovasc Prev Rehabil 2007;14:28–36CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Torsten Toftegaard Nielsen
    • 1
  1. 1.Aarhus University HospitalDenmark

Personalised recommendations